Remeditex Ventures, set up in part by technology transfer professionals at Texas University's UT Southwestern Medical Center, is joined by Amgen's corporate venturing unit backing the round.
Remeditex Ventures, a US-based venture capital (VC) firm set up by former executives at Hunt Petroleum and technology transfer professionals at Texas University’s UT Southwestern Medical Center, led a $20m round for MiRagen Therapeutics, a US-based biopharmaceutical firm to treat muscle disease.
Remeditex was joined in its series B round by Amgen Ventures, the corporate venturing division of biotechnology corporation Amgen and venture peers Atlas Venture, Boulder Ventures and Broadview Ventures.
Miragen picked up an initial $4m of funding…
